Cargando…

Management of patients with lower-risk myelodysplastic syndromes

Myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic stem cell disorders characterized by ineffective hematopoiesis with abnormal blood cell development (dysplasia) leading to cytopenias and an increased risk for progression to acute myeloid leukemia (AML). Patients with MDS ca...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brunner, Andrew M., Leitch, Heather A., van de Loosdrecht, Arjan A., Bonadies, Nicolas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751093/ https://www.ncbi.nlm.nih.gov/pubmed/36517487 http://dx.doi.org/10.1038/s41408-022-00765-8

Ejemplares similares

EHA Endorsement of ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up for Myelodysplastic Syndromes
por: van de Loosdrecht, Arjan A., et al.
Publicado: (2022)

Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes
por: de Swart, Louise, et al.
Publicado: (2018)

Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS)
por: Lucero, Josephine, et al.
Publicado: (2023)

Higher Risk Myelodysplastic Syndromes in Patients with Well-Controlled HIV Infection: Clinical Features, Treatment, and Outcome
por: Williamson, Bradley T., et al.
Publicado: (2016)

Management of infection prophylaxis in Dutch patients with myelodysplastic syndromes, a web‐based case vignette questionnaire: The MINDSET study
por: Rozema, Johanne, et al.
Publicado: (2022)

Role of Luspatercept in the Management of Lower-Risk Myelodysplastic Syndromes
por: Tinsley-Vance, Sara M., et al.
Publicado: (2023)

Thrombomodulin-expressing monocytes are associated with low-risk features in myelodysplastic syndromes and dampen excessive immune activation
por: van Leeuwen-Kerkhoff, Nathalie, et al.
Publicado: (2020)

Computational flow cytometry as a diagnostic tool in suspected‐myelodysplastic syndromes
por: Duetz, Carolien, et al.
Publicado: (2021)

Challenging the status flow: how artificial intelligence is advancing diagnosis of myelodysplastic neoplasms
por: Duetz, Carolien, et al.
Publicado: (2023)

Standards and Impact of Hematopathology in Myelodysplastic Syndromes (MDS)
por: Valent, Peter, et al.
Publicado: (2010)

Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry
por: Hoeks, Marlijn, et al.
Publicado: (2020)

Lower‐risk myelodysplastic syndromes: Current treatment options for anemia
por: Meunier, Mathieu, et al.
Publicado: (2022)

Erythropoiesis‐stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower‐risk myelodysplastic syndrome
por: Garelius, H. K. G., et al.
Publicado: (2016)

Increased prescription rate of anti‐infective agents after diagnosis of myelodysplastic syndromes
por: Rozema, Johanne, et al.
Publicado: (2022)

Autoimmune Syndromes Presenting as a Paraneoplastic Manifestation of Myelodysplastic Syndromes: Clinical Features, Course, Treatment and Outcome
por: Williamson, Bradley T., et al.
Publicado: (2016)

Treatment options for lower-risk myelodysplastic syndromes. Where are we now?
por: Volpe, Virginia O., et al.
Publicado: (2021)

Durable Responses and Survival in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients Receiving the Allogeneic Leukemia-derived Dendritic Cell Vaccine DCP-001
por: Janssen, Luca L.G., et al.
Publicado: (2023)

Reduced frequencies and functional impairment of dendritic cell subsets and non-classical monocytes in myelodysplastic syndromes
por: van Leeuwen-Kerkhoff, Nathalie, et al.
Publicado: (2021)

Survey on Recommended Health Care for Adult Patients with Myelodysplastic Syndromes Identifies Areas for Improvement
por: Chanias, Ioannis, et al.
Publicado: (2020)

Myelodysplastic Syndromes in the Postgenomic Era and Future Perspectives for Precision Medicine
por: Chanias, Ioannis, et al.
Publicado: (2021)

EASIX for prediction of survival in lower-risk myelodysplastic syndromes
por: Merz, Almuth, et al.
Publicado: (2019)

Analysis of the impact of adherence to guidelines and expert advice in patients with myelodysplastic syndromes
por: Kasprzak, A., et al.
Publicado: (2020)

Red Blood Cell Transfusion Independence Following the Initiation of Iron Chelation Therapy in Myelodysplastic Syndrome
por: Badawi, Maha A., et al.
Publicado: (2010)

Immunophenotypic aberrant hematopoietic stem cells in myelodysplastic syndromes: a biomarker for leukemic progression
por: van Spronsen, Margot F., et al.
Publicado: (2023)

Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes
por: Komrokji, R. S., et al.
Publicado: (2016)

Abnormal Dendritic Cell-poiesis in Patients With Lower-risk Myelodysplastic Syndromes
por: Sánchez, Ángela, et al.
Publicado: (2020)

Is 6-Shogaol an Effective Phytochemical for Patients With Lower-risk Myelodysplastic Syndrome? A Narrative Review
por: Ooi, Soo Liang, et al.
Publicado: (2021)

Prediction of response to therapy with ezatiostat in lower risk myelodysplastic syndrome
por: Galili, Naomi, et al.
Publicado: (2012)

A series of case studies illustrating the role of flow cytometry in the diagnostic work‐up of myelodysplastic syndromes
por: Westers, Theresia M., et al.
Publicado: (2022)

Clinical management of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes
por: Clara, Joseph A., et al.
Publicado: (2016)

Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes
por: Komrokji, Rami S., et al.
Publicado: (2023)

Managing myelodysplastic symptoms in elderly patients
por: Ria, R, et al.
Publicado: (2009)

Content validity of patient-reported outcomes for use in lower-risk myelodysplastic syndromes
por: Trudeau, Jeremiah J., et al.
Publicado: (2020)

Prognostic impact of immunophenotypic aberrancies of blasts in lower risk myelodysplastic syndrome
por: Corrao, Kristen, et al.
Publicado: (2022)

Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome
por: Hoeks, Marlijn, et al.
Publicado: (2020)

The role of azacitidine in the management of myelodysplastic syndromes (MDS)
por: Götze, KS, et al.
Publicado: (2009)

Genetics of Myelodysplastic Syndromes
por: Saygin, Caner, et al.
Publicado: (2021)

S169: MODULATION OF THE IMMUNE LANDSCAPE IN LOWER-RISK MYELODYSPLASTIC SYNDROMES WITH IMETELSTAT-INDUCED TRANSFUSION INDEPENDENCY
por: Chapuis, Nicolas, et al.
Publicado: (2023)

Setting Fire to ESA and EMA Resistance: New Targeted Treatment Options in Lower Risk Myelodysplastic Syndromes
por: Kubasch, Anne Sophie, et al.
Publicado: (2019)

Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions
por: Valent, Peter, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_diemoj849sdjt8mstuojg4njje